# A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

> **NCT04471727** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 232 (estimated)

## Conditions studied

- Small-Cell Lung Cancer
- Neuroendocrine Carcinoma

## Interventions

- **BIOLOGICAL:** Gocatamig
- **BIOLOGICAL:** Atezolizumab
- **BIOLOGICAL:** Ifinatamab Deruxtecan (I-DXd)

## Key facts

- **NCT ID:** NCT04471727
- **Lead sponsor:** Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-14
- **Primary completion:** 2028-01-28
- **Final completion:** 2028-01-28
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471727, "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04471727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*